PortfoliosLab logoPortfoliosLab logo
IPO Date
Mar 1, 1999

Highlights

Market Cap
$3.82M
Enterprise Value
-$3.55M
EPS (TTM)
-$6.65
Total Revenue (TTM)
-$725.20K
Gross Profit (TTM)
-$2.86M
EBITDA (TTM)
-$14.65M
Year Range
$1.77 - $11.87
ROA (TTM)
-117.96%
ROE (TTM)
-205.25%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Imunon Inc

Performance

IMNN Performance Chart

Imunon Inc (IMNN) is down 52.8% since the beginning of the year. At $2 per share, IMNN is trading 84.8% below its 52-week high of $12. Investors who bought $1,000 worth of IMNN shares 5 years ago would now be looking at an investment worth $7.


Loading charts...

S&P 500 Index

Returns By Period

Imunon Inc (IMNN) has returned -52.76% so far this year and -86.47% over the past 12 months. Over the last ten years, IMNN has returned -53.08% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.


Imunon Inc

1D
-1.10%
1M
-18.18%
YTD
-52.76%
6M
-51.74%
1Y
-86.47%
3Y*
-52.28%
5Y*
-62.56%
10Y*
-53.08%

Benchmark (S&P 500 Index)

1D
-0.37%
1M
-0.01%
YTD
9.16%
6M
8.64%
1Y
25.22%
3Y*
19.78%
5Y*
11.99%
10Y*
13.88%
*Multi-year figures are annualized to reflect compound growth (CAGR)

IMNN Monthly Returns History

Based on dividend-adjusted daily data since Mar 1, 1999, IMNN's average daily return is +0.06%, while the average monthly return is +0.70%. At this rate, an investment would double in approximately 8.3 years.

Historically, 38% of months were positive and 62% were negative. The best month was Dec 1999 with a return of +267.5%, while the worst month was Jan 2013 at -81.6%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 13 months.

On a daily basis, IMNN closed higher 40% of trading days. The best single day was Oct 3, 2017 with a return of +301.3%, while the worst single day was Jan 31, 2013 at -81.2%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-12.86%-2.11%-9.54%-3.74%-22.97%-17.43%-52.76%
2025-6.84%0.64%17.88%-20.00%196.43%-67.87%-30.92%-17.74%-13.49%-11.31%-9.45%-7.52%-69.25%
2024-24.12%120.93%43.86%-20.12%9.92%-19.44%16.38%-14.81%-7.83%-12.26%-9.68%13.10%39.71%
202317.04%-10.13%-12.68%5.98%-10.20%9.32%-2.33%-0.79%-21.41%0.77%-9.09%-24.44%-49.63%
2022-12.06%-31.86%4.24%-42.69%-15.86%-24.59%18.48%-2.29%-21.13%-10.12%-5.96%-4.93%-83.33%
202192.69%50.36%-33.01%-14.49%0.00%7.63%-12.60%-4.50%-12.79%-1.93%-15.16%-29.80%-24.05%

Benchmark Metrics

Imunon Inc has an annualized alpha of 11.54%, beta of 0.50, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since March 01, 1999.

  • This stock participated in 188.06% of S&P 500 Index downside but only 7.93% of its upside - more exposed to losses than it benefited from rallies.
  • Beta of 0.50 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
11.54%
Beta
0.50
0.01
Upside Capture
7.93%
Downside Capture
188.06%

Return for Risk

Risk / Return Rank

IMNN ranks 3 for risk / return — in the bottom 3% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.


IMNN Risk / Return Rank: 33
Overall Rank
IMNN Sharpe Ratio Rank: 11
Sharpe Ratio Rank
IMNN Sortino Ratio Rank: 00
Sortino Ratio Rank
IMNN Omega Ratio Rank: 11
Omega Ratio Rank
IMNN Calmar Ratio Rank: 00
Calmar Ratio Rank
IMNN Martin Ratio Rank: 1111
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Imunon Inc (IMNN) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


IMNNBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-3.34

Sortino ratioReturn per unit of downside risk

-6.34

Omega ratioGain probability vs. loss probability

0.61

1.37

-0.75

Calmar ratioReturn relative to maximum drawdown

-1.02

2.78

-3.80

Martin ratioReturn relative to average drawdown

-1.32

12.44

-13.76

Dividends

Dividend History


Imunon Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Imunon Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Imunon Inc was 100.00%, occurring on Jun 22, 2026. The portfolio has not yet recovered.

The current Imunon Inc drawdown is 100.00%.


Related event

Drawdown

Fall

Recovery

Underwater

2026 bear market2026
-100.00%Jun 2026
26y 3mo
26y 3moMar 2000 - now
2000 bear market2000
-39.67%Jan 2000
9d29d
1mo 8dJan 2000 - Feb 2000
1999 bear market1999
-37.50%Nov 1999
3mo 27d1mo 5d
5mo 2dJul 1999 - Dec 1999
1999 bear market1999
-33.68%Dec 1999
1d12d
13dDec 1999 - Dec 1999
1999 bear market1999
-25.51%May 1999
2mo 14d1mo 29d
4mo 13dMar 1999 - Jul 1999

Drawdown Indicators


IMNNBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-100.00%

-56.78%

-43.22%

Max Drawdown (1Y)

Largest decline over 1 year

-85.03%

-9.10%

-75.93%

Max Drawdown (3Y)

Largest decline over 3 years

-95.84%

-18.90%

-76.94%

Max Drawdown (5Y)

Largest decline over 5 years

-99.30%

-25.43%

-73.87%

Max Drawdown (10Y)

Largest decline over 10 years

-99.95%

-33.92%

-66.03%

Current Drawdown

Current decline from peak

-100.00%

-1.80%

-98.20%

Average Drawdown

Average peak-to-trough decline

-93.79%

-10.71%

-83.08%

Ulcer Index

Depth and duration of drawdowns from previous peaks

68.32%

2.03%

+66.29%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Imunon Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Imunon Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for IMNN in comparison with other companies in the Biotechnology industry. Currently, IMNN has a P/B value of 0.5. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with IMNN

Add Imunon Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with IMNN